Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
Oncotarget|November 5, 2017
Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev)Pierpaolo Pastina, Valerio Nardone, Cirino Botta, et al.
Oncoimmunology|May 4, 2016
Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patientsPierpaolo Correale, Cirino Botta, Elodia Claudio Martino, et al.
Emerging Infectious Diseases|March 23, 2022
Infectious Toscana Virus in Seminal Fluid of Young Man Returning from Elba Island, ItalyGiulia Matusali, Alessandra D'Abramo, Chiara Terrosi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 9, 2005
Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitroPierpaolo Correale, Maria Grazia Cusi, Maria Teresa Del Vecchio, et al.
Cancer Immunology, Immunotherapy : CII|June 3, 2015
Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patientsMaria Grazia Cusi, Cirino Botta, Pierpaolo Pastina, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 1, 2020
Residual SARS-CoV-2 RNA in nasal swabs of convalescent COVID-19 patients: Is prolonged quarantine always justified?Antonio Piralla, Matteo Ricchi, Maria Grazia Cusi, et al.
Oncotarget|May 15, 2018
Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccinePierpaolo Correale, Cirino Botta, Nicoletta Staropoli, et al.
The New Microbiologica|June 21, 2021
Hepatitis C Virus Core Antigen (HCVAg): an affordable assay to monitor the efficacy of treatment in DAAs eraBarbara Rossetti, Elisabetta Loggi, Chiara Spertilli Raffaelli, et al.
Journal of Clinical Immunology|July 2, 2022
Long-term SARS-CoV-2 Asymptomatic Carriage in an Immunocompromised Host: Clinical, Immunological, and Virological ImplicationsMichele Spinicci, Alessio Mazzoni, Marco Coppi, et al.
Journal of Thoracic Disease|December 10, 2017
Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patientsPierpaolo Pastina, Valerio Nardone, Stefania Croci, et al.
Pageof 11